Stocktoria
Akebia Therapeutics, Inc. AKBA
Akebia Therapeutics, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $236.2M | $160.2M | $194.6M | $292.5M | $213.6M | $295.3M | $335.0M | $207.7M | $181.2M | $1.5M |
| R&D expense | $62.4M | $37.7M | $63.1M | $130.0M | $147.9M | $218.5M | $323.0M | $291.0M | $230.9M | $115.8M |
| SG&A expense | $107.5M | $106.5M | $100.2M | $138.6M | $174.2M | $153.9M | $149.5M | $87.1M | $27.0M | $22.2M |
| Operating income | $23.5M | -$50.5M | -$46.3M | -$80.8M | -$265.3M | -$376.4M | -$286.3M | -$178.2M | -$76.7M | -$136.5M |
| Income tax | $1.6M | $0 | $0 | $0 | $0 | $0 | -$6.6M | -$28.3M | — | — |
| Net income | -$5.3M | -$69.4M | -$51.9M | -$94.2M | -$282.0M | -$383.5M | -$279.7M | -$143.6M | -$73.7M | -$135.7M |
| EPS (diluted) | $-0.02 | $-0.33 | $-0.28 | $-0.52 | $-1.70 | $-2.77 | $-2.36 | — | — | — |
| Operating cash flow | $68.0M | -$40.7M | -$23.4M | -$73.2M | -$253.0M | -$110.4M | -$257.4M | -$97.5M | -$56.2M | $57.9M |
| Free cash flow | $67.7M | -$40.7M | -$23.4M | -$73.3M | -$253.0M | -$110.7M | -$264.1M | -$99.1M | -$57.8M | $55.2M |
| Cash & equivalents | $184.8M | $51.9M | $42.9M | $90.5M | $149.8M | $228.7M | $147.4M | $104.6M | $70.2M | $187.3M |
| Inventory | $15.6M | $16.2M | $15.7M | $21.6M | $38.2M | $61.0M | $116.3M | $114.2M | — | — |
| Total assets | $376.6M | $220.7M | $241.7M | $356.1M | $525.5M | $644.1M | $771.2M | $996.5M | $364.2M | $300.2M |
| Total liabilities | $344.0M | $269.9M | $272.3M | $350.8M | $449.1M | $396.5M | $376.4M | $360.6M | $241.7M | $232.1M |
| Shareholders' equity | $32.6M | -$49.2M | -$30.6M | $5.2M | $74.0M | $247.6M | $394.8M | $635.9M | $122.6M | $68.1M |
Growth · year-over-year · Revenue CAGR 75%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +47.5% | -17.7% | -33.5% | +36.9% | -27.7% | -11.8% | +61.3% | +14.6% | +11706.3% | — |
| Free cash flow growth | — | — | — | — | — | — | — | — | -204.6% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.